The test consists of a 72 h supervised fast in an inpatient setting with ongoing monitoring of plasma glucose, insulin, and C-peptide levels with or without beta-hydroxybutyrate until hypoglycemia occurs. This evidence concerns the gene INS and Hypoglycemia.